Effect of an oral contraceptive containing 30 μg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention

Contraception

Volumn 76, Issue 3, 2007, Pages 190-194

  Fruzzetti, Franca ^a   Lazzarini, Veronica ^a   Ricci, Cabiria ^a   Quirici, Barbara ^a   Gambacciani, Marco ^a   Paoletti, Anna Maria ^b   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Body composition; Drospirenone; Multifrequency bioelectrical impedance; Oral contraceptives; Premenstrual water retention symptoms

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; WATER;

ADULT; ARTICLE; BIOENERGY; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EXTRACELLULAR FLUID; FEMALE; HUMAN; IMPEDANCE; LUTEAL PHASE; MEDICAL PARAMETERS; MENSTRUAL CYCLE; ORAL CONTRACEPTION; PREMENSTRUAL SYNDROME; PROSPECTIVE STUDY; TOTAL BODY WATER; WAIST HIP RATIO; WATER RETENTION;

ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; BODY FLUID COMPARTMENTS; CASE-CONTROL STUDIES; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; PREMENSTRUAL SYNDROME; PROSPECTIVE STUDIES;

EID: 34547837619     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.05.080     Document Type: Article

References (31)

1. Ross C., Coleman G., and Stojanovska C. Prospectively reported symptom change across the menstrual cycle in users and non-users of oral contraceptives. J Psychosom Obstet Gynaecol 24 (2003) 15-29
2. Reid R. Premenstrual syndrome. N Engl J Med 324 (1991) 1208-1210
3. Mortola J.F., Girton L., Beck L., et al. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol 76 (1990) 302-307
4. ACOG Practice Bulletin. Premenstrual syndrome (2000), American College of Obstetricians and Gynecologist, Washington (DC)
5. Harrison W.M., Rabkin J.G., and Endicott J. Psychiatric evaluation of premenstrual changes. Psychosomatics 26 (1985) 798-799
6. Barnhart K.T., Freemena E.W., and Sondheimer S.J. A clinician's guide to the premenstrual syndrome. Med Clin North Am 79 (1995) 1457-1472
7. Kroll R., and Rapkin A.J. Treatment of premenstrual disorders. J Reprod Med 51 4 Suppl (2006) 359-370 [Review]
8. Labad J., Menchon J.M., Alonso P., Segalas C., Jimenez S., and Vallejo J. Oral contraceptive pill use and changes in obsessive-compulsive symptoms. J Psychosom Res 60 (2006) 647-648
9. Winkler U.H., Ferguson H., and Mulders J.A. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 μg ethinylestradiol. Contraception 69 (2004) 469-476
10. Joffe H., Cohen L.S., and Harlow B.L. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 189 (2003) 1523-1530
11. Graham C.A., and Sherwin B.B. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 36 (1992) 257-266
12. Bäckström T., Hansson-Malmström Y., Lindhe B.Å., Cavalli-Björkman B., and Nordenström D. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 46 (1992) 253-268
13. Borenstein J., Yu H.T., Wade S., Chiou C.F., and Rapkin A. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 48 (2003) 79-85
14. Foidart J.M. Added benefits of drospirenone for compliance. Climacteric 8 Suppl 3 (2005) 28-34
15. Apter D., Borsos A., Baumgartner W., et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 8 (2003) 37-51
16. Mansour D. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being. Eur J Contracept Reprod Health Care 7 Suppl 3 (2002) 35-41
17. Crane M.G., and Harris J.J. Effect of oestrogens and gestagens on exchangeable sodium. In: Fregly M.J., and Fregly M.S. (Eds). Oral contraceptives and high blood pressure (1974), Dolphin Press, Gainesville (Fla) 159-169
18. Elger W., Beier S., Pollow K., et al. Conception and pharmacological profile of drospirenone. Steroids 68 (2003) 891-905
19. Oelkers W., Berger V., Bolik A., et al. Dihydrospirenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 73 (1991) 837-842
20. Philibert D., Bouchoux F., Degryse M., et al. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 13 (1999) 316-326
21. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62 (2000) 29-38
22. Elger W., Steinbeck H., Schillinger E., et al. Endocrine pharmacological profile of gestodene. In: Elstein E. (Ed). Gestodene. Development of a new gestodene-containing low dose oral contraceptive (1987), Parthenon Publishing, Carnforth (UK) 19-33
23. Kyle U.G., Bosaeus I., De Lorenzo A.D., et al. Bioelectrical impedance analysis - part II: utilization in clinical practice. Clin Nutr 23 (2004) 1430-1453
24. Martinoli R., Mohamed E.I., Maiolo C., et al. Total body water estimation using bioelectrical impedance: a meta-analysis of the data available in the literature. Acta Diabetol 40 Suppl 1 (2003) S203-S206
25. Gudivaka R., Schoeller D.A., Kushner R.F., and Bolt M.J. Single and multifrequency model for bioelectrical impedance analysis of body water compartments. J Appl Physiol 87 (1999) 1087-1096
26. Stachenfeld N.S., DiPietro L., Kokoszka C.A., Silca C., Keef D.L., and Nadel E.R. Physiological variability of fluid-regulation hormones in young women. J Appl Physiol 86 (1999) 1092-1096
27. Stachenfeld N.S., and Taylor H.S. Effect of estrogen and progesterone administration on extracellular fluid. J Appl Physiol 96 (2004) 1011-1018
28. Oelkers W.K. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 61 (1996) 166-171
29. Tollan A., Oian P., Fadnes H.O., and Maltau J.M. Evidence for altered transcapillary fluid balance in women with the premenstrual syndrome. Acta Obstet Gynecol Scand 72 (1993) 238-242
30. Munday M.R., Brush M.G., and Taylor R.W. Correlations between progesterone, oestradiol and aldosterone levels in the premenstrual syndrome. Clin Endocrinol (Oxf) 14 (1981) 1-9
31. Fruzzetti F., Lello S., Lazzarini V., et al. The oral contraceptive containing 30 μg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception 75 (2007) 199-203